Evidence map›Paper›PMID 38064042›Full record

ArticleBiotechnology letters2024

Production of D-glucaric acid with phosphoglucose isomerase-deficient Saccharomyces cerevisiae.

Mervi Toivari, Maija-Leena Vehkomäki, Laura Ruohonen, Merja Penttilä, Marilyn G Wiebe

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mervi ToivariVTT Technical Research Centre of Finland Ltd, Tekniikantie 21, P.O. Box 1000, 02044, Espoo, Finland. mervi.toivari@vtt.fi.ORCID http://orcid.org/0000-0002-5477-6416
Maija-Leena VehkomäkiVTT Technical Research Centre of Finland Ltd, Tekniikantie 21, P.O. Box 1000, 02044, Espoo, Finland.
Laura RuohonenVTT Technical Research Centre of Finland Ltd, Tekniikantie 21, P.O. Box 1000, 02044, Espoo, Finland.
Merja PenttiläVTT Technical Research Centre of Finland Ltd, Tekniikantie 21, P.O. Box 1000, 02044, Espoo, Finland.
Marilyn G WiebeVTT Technical Research Centre of Finland Ltd, Tekniikantie 21, P.O. Box 1000, 02044, Espoo, Finland.
VTT Technical Research Centre of Finland · FI

Funding

Academy of Finland 118573Academy of Finland 310191European comission FP7-241566
6 · The paper itself

Abstract

D-Glucaric acid is a potential biobased platform chemical. Previously mainly Escherichia coli, but also the yeast Saccharomyces cerevisiae, and Pichia pastoris, have been engineered for conversion of D-glucose to D-glucaric acid via myo-inositol. One reason for low yields from the yeast strains is the strong flux towards glycolysis. Thus, to decrease the flux of D-glucose to biomass, and to increase D-glucaric acid yield, the four step D-glucaric acid pathway was introduced into a phosphoglucose isomerase deficient (Pgi1p-deficient) Saccharomyces cerevisiae strain. High D-glucose concentrations are toxic to the Pgi1p-deficient strains, so various feeding strategies and use of polymeric substrates were studied. Uniformly labelled

Indexed as

Glucose-6-Phosphate IsomeraseSaccharomyces cerevisiaeEscherichia coliGlucaric AcidGlucoseInositolGlucaric AcidGlucoseGlucose-6-Phosphate IsomeraseInositolGlucarateGlucaric acidMetabolic engineeringMyo-inositolPhosphoglucose isomeraseSaccharomyces cerevisiae

Identifiers

PMID38064042
PMCPMC10787697
OpenAlexW4389482703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.